These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Molecular Engineering of an Organic NIR-II Fluorophore with Aggregation-Induced Emission Characteristics for In Vivo Imaging.
    Author: Wu W, Yang Y, Yang Y, Yang Y, Zhang K, Guo L, Ge H, Chen X, Liu J, Feng H.
    Journal: Small; 2019 May; 15(20):e1805549. PubMed ID: 30925013.
    Abstract:
    Design and synthesis of new fluorophores with emission in the second near-infrared window (NIR-II, 1000-1700 nm) have fueled the advancement of in vivo fluorescence imaging. Organic NIR-II probes particularly attract tremendous attention due to excellent stability and biocompatibility, which facilitate clinical translation. However, reported organic NIR-II fluorescent agents often suffer from low quantum yield and complicated design. In this study, the acceptor unit of a known NIR-I aggregation-induced emission (AIE) luminogen (AIEgen) is molecularly engineered by varying a single atom from sulfur to selenium, leading to redshifted absorption and emission spectra. After formulation of the newly prepared AIEgen, the resultant AIE nanoparticles (referred as L897 NPs) have an emission tail extending to 1200 nm with a high quantum yield of 5.8%. Based on the L897 NPs, noninvasive vessel imaging and lymphatic imaging are achieved with high signal-to-background ratio and deep penetration. Furthermore, the L897 NPs can be used as good contrast agents for tumor imaging and image-guided surgery due to the high tumor/normal tissue ratio, which peaks at 9.0 ± 0.6. This work suggests a simple strategy for designing and manufacturing NIR-II AIEgens and demonstrates the potential of NIR-II AIEgens in vessel, lymphatic, and tumor imaging.
    [Abstract] [Full Text] [Related] [New Search]